A. Breazna

发表

versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization Statistical Analysis Plan ( Part I : Methodology ) Version 6 . 0 January , 26 2016

Melissa Nichols, A. Breazna, 2011 .

Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

R. Finn, T. Pintér, J. Crown, 2012 .

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial

Heather B. Gonzalez, John D. Davis, Travis J. Bernardo, 2022, The Lancet Infectious Diseases.

Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.

G. Demetri, R. Motzer, T. Suter, 2014, European journal of cancer.

A Novel Composite Endpoint to Evaluate the Gastrointestinal (GI) Effects of Nonsteroidal Antiinflammatory Drugs Through the Entire GI Tract

F. Chan, Á. Lanas, L. Simon, 2010, Journal of Rheumatology.

New drug development

O. S. Zhukova, Guy Jerusalem, Robert Millham, 2012 .

A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study

D. Frappaz, B. Geoerger, J. Grill, 2013, Journal of Neuro-Oncology.

Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.

B. Geoerger, J. Grill, D. Hargrave, 2013, Neuro-oncology.

Five-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps Trial

B. Levin, N. Arber, M. Zavoral, 2011, The American Journal of Gastroenterology.

Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial

A. Zauber, M. Bertagnolli, E. Hawk, 2009, Cancer Prevention Research.

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

A. Zauber, M. Bertagnolli, E. Hawk, 2009, Gastroenterology.

A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors

E. Heath, P. LoRusso, E. Sadowski, 2016, Cancer Chemotherapy and Pharmacology.

Treatment of Osteoarthritis with Continuous Versus Intermittent Celecoxib

M. Dougados, V. Strand, L. Simon, 2011, The Journal of Rheumatology.

Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST

G. Demetri, Yoon-Koo Kang, P. Reichardt, 2008 .

P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer.

D. Amadori, R. Finn, T. Pintér, 2011 .

Five-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps Trial

B. Levin, N. Arber, M. Zavoral, 2011 .

Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain

L. Macdonald, A. Murphy, S. Rottey, 2023, Neurobiology of pain.

Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.

B. Joondeph, J. Pearlman, C. Wykoff, 2023, JAMA ophthalmology.

Abstract A177: Phase 1, dose-escalation, safety, pharmacokinetic and pharmacodynamic study of single agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumors.

L. Mileshkin, L. Rosen, J. Goldman, 2011 .